- Company
- Clotinab, exclusive in the bio-anti-hemolysis market
- by Nho, Byung Chul Feb 1, 2023 05:54am
- In the anti-hemorrhagic biopharmaceutical market, Korean biosimilar Clotinab is dominating the market. According to data on drug distribution performance, ISU ABXIS Clotinab's 2021 performance was 2.8 billion won, dominating the Abciximab biosimilar market. The sales of the product in 2018, 2019, and 2020 are 3,048 million won, 2,920 million
- Company
- Imfinzi expands biliary cancer indication
- by Feb 1, 2023 05:54am
- "Although there are few clinical patients, effectiveness improvement and safety performance" A new option for immuno-cancer drugs has been born in biliary tract cancer, where chemotherapy has long been the standard treatment. The medical staff said, "We improved the treatment of biliary tract cancer, which has not progressed for more than 10
- Company
- Sales of statin-ezetimibe combo rise threefold in 3 yrs
- by Chon, Seung-Hyun Feb 1, 2023 05:54am
- Statin-ezetimibe combination drugs greatly expanded their influence in Korea’s dyslipidemia treatment market. Their total prescription amount increased by over threefold in the past 5 years, and its annual market size exceeds KRW 750 billion. In the market, rosuvastatin-ezetimibe combinations drove market growth, and the bulk of generic atorvas
- Company
- Merck makes large investments in Korea’s science tech
- by Jan 31, 2023 05:59am
- With President Suk Yeol Yoon prioritizing fostering talent in science and technology as the government’s key task, one global company has attracted attention for being committed to strengthening domestic talent in science and technology in Korea. According to industry sources on the 31st, Merck Life Sciences, a global life science com
- Company
- MSD Korea to replace its leader for the first time in 2 yrs
- by Jan 31, 2023 05:59am
- The head of MSD Korea will be replaced for the first time in about two years. Kevin Peters, the current president, will leave Korea at the end of this month. According to the pharmaceutical industry on the 28th, Kevin Peters, CEO of MSD Korea, will be appointed as the general representative of the German branch from February. It has been two
- Company
- HKinno.N exports new drug K-CAB technology to Brazil
- by Chon, Seung-Hyun Jan 30, 2023 05:54am
- HKinno.N announced on the 26th that it has signed a technology export contract with Brazilian pharmaceutical company Eurofarma for the new drug K-CAB for gastroesophageal reflux disease. HKinno.N will transfer the manufacturing technology of K-CAB to Eurofarma, and Eurofarma will develop and sell K-CAB in Brazil. Along with the down payment,
- Company
- SK Bioscience proposes building a vaccine hub in Middle East
- by Jan 30, 2023 05:54am
- SK Bioscience announced on the 27th that the company’s CEO, Jae-Yong Ahn, participated in the ‘2023 Riyadh Global Medical Biotechnology Summit’ that was held in Riyadh, the capital of the Kingdom of Saudi Arabia, and proposed a partnership for vaccine supply on the 25th (local time). The Riyadh Summit, which celebrated its second ev
- Company
- Practice manual issued for COVID-19 treatments in Korea
- by Jan 30, 2023 05:54am
- Doctors have issued a ‘Practice Manual’ to provide an understanding of how to use the COVID-19 treatment in one glance. The manual was prepared to directly address difficulties HCPs experienced prescribing COVID-19 treatments in the field due to a large number of contraindicated drugs. The Korean Society for Antimicrobial Therapy (KSAT) rec
- Company
- HK inno.N introduces biosimilar for Prolia & Xgeva
- by Lee, Seok-Jun Jan 27, 2023 05:51am
- HK inno.N announced on the 25th that it has signed an exclusive license contract for Denosumab biosimilar, a treatment for preventing osteoporosis and cancer-related skeletal complications in Mabxience, Spain. HK inno.N will receive an exclusive supply of two Denosumab biosimilars from Mabxience to apply for and sell domestic licenses. Denosu
- Company
- Flu activity rises...revives Tamiflu market
- by Jan 27, 2023 05:51am
- The influenza treatment market, which had virtually disappeared after the spread of COVID-19, has revived for the first time in 3 years. With the number of flu patients surging due to the flu epidemic, the number of quarterly prescriptions soared from less than KRW 100 million to KRW 10 billion. According to the market research institution UB
